Any feedback?
Literature summary for 3.4.21.5 extracted from
- A novel hirudin derivative characterized with anti-platelet aggregations and thrombin inhibition (2008), J. Thromb. Thrombolysis, 28, 230-237.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | rabbits receiving infusions with recombinant hirudin containing the RGD motif, which competitively inhibits the binding of fibrinogen to GP IIb/IIIa on platelets, have prolonged thrombin time, prothrombin time. and activated partial thromboplastin time which are similar to that of wild-type hirudin. In addition, recombinant RGD-hirudin is capable of inhibiting platelet aggregation and is two to three times more effective than wild-type hirudin in preventing thrombosis | Oryctolagus cuniculus |
Inhibitors
| Inhibitors | Comment | Organism | Structure |
|---|---|---|---|
| Hirudin | - |
Oryctolagus cuniculus | |
| RGD-hirudin | recombinant hirudin containing the RGD motif which competitively inhibits the binding of fibrinogen to GP IIb/IIIa on platelets. Specific anti-thrombin activity of RGD-hirudin is 12000 ATU/mg and equivalent to native hirudin, and it addiotionally inhibits platelet aggregation | Oryctolagus cuniculus |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Oryctolagus cuniculus | - |
- |
- |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
